Week 4 on Mounjaro or Ozempic: what the timeline actually looks like

What did @itsjessicablodgett actually say?

Jessica is four weeks into tirzepatide (Mounjaro) after a rough experience with semaglutide (Ozempic). She previously had gastric sleeve surgery in 2017, lost over 100 pounds, then regained some weight as her stomach stretched over time. Her core claim: Mounjaro is "literally giving me that restriction back" — the same physical fullness she felt in her first post-surgery year. She reports losing 10 pounds in three weeks with no dietary changes and zero side effects. She also describes the mental shift: her brain is no longer "obsessed with thinking about snacks or food."

She's not making wild medical promises. She's describing her personal experience in language that's specific, grounded, and mostly consistent with what the pharmacology of tirzepatide actually does. That's worth acknowledging before picking it apart.

Does the science back this up?

The "restriction" framing is mechanistically plausible, though it's not the whole picture. Tirzepatide slows gastric emptying and reduces appetite through GIP and GLP-1 receptor agonism — effects that do mimic some of what bariatric surgery achieves, but through different pathways.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at higher doses producing up to 22.5% mean body weight reduction in adults with obesity. The appetite suppression Jessica describes — that quieting of food-focused thoughts — maps onto what researchers call "food noise" reduction, which has been documented qualitatively in GLP-1 and GIP/GLP-1 studies, though it's not yet well-characterized in formal outcome measures.

Her 10-pound loss in three weeks is on the faster end but not implausible, especially with the added metabolic context of prior bariatric surgery. Some research suggests GLP-1 receptor agonists may work differently in post-bariatric patients, with at least one analysis noting altered gut hormone responses after sleeve gastrectomy (Laferrère et al., 2011, Diabetes Care).

What did they get wrong (or right)?

She got the experiential description largely right. The comparison between tirzepatide's appetite suppression and early post-sleeve restriction is a reasonable lay analogy. Gastric sleeve surgery does reduce ghrelin-producing cells and restricts volume, and both mechanisms converge on reduced hunger and earlier satiety — similar endpoints to what GLP-1/GIP agonism achieves pharmacologically.

Where she oversimplifies: saying she's "changed nothing else" but attributing results entirely to restriction. Tirzepatide's weight loss mechanism isn't purely physical restriction — it's also central appetite regulation, insulin sensitization, and shifts in energy metabolism. The stomach-tightening framing undersells the drug's systemic effects.

The bigger flag is "no side effects." Tirzepatide's most common adverse effects — nausea, vomiting, constipation, diarrhea — affect a significant portion of users, particularly in the first weeks. SURMOUNT-1 reported gastrointestinal side effects in roughly 40-60% of participants depending on dose. Her experience may be genuine, but presenting zero side effects as the expected outcome could set unrealistic expectations for new users.

What should you actually know?

A few things Jessica didn't mention that matter if you're considering this medication.

• Tirzepatide and semaglutide are not interchangeable. They work on different receptor combinations — tirzepatide hits both GIP and GLP-1 receptors, semaglutide targets GLP-1 only. Tolerating one poorly does not predict how you'll do on the other, which actually supports her experience of switching.
• Post-bariatric patients using GLP-1 or dual agonist medications are a specific subpopulation with limited dedicated trial data. Clinicians managing these patients should account for altered absorption, baseline gut hormone changes, and the psychological history tied to weight regain after surgery.
• Compounded tirzepatide and brand-name Mounjaro are not equivalent products. If you're sourcing tirzepatide outside of a regulated pharmacy, that's a different risk profile entirely.
• Ten pounds in three weeks includes a meaningful amount of water weight and glycogen depletion, especially early in treatment. Long-term results require sustained use and, typically, lifestyle adjustment — the "changed nothing" framing applies early, not forever.

The bottom line

Jessica's video is one of the more medically coherent GLP-1 testimonials on TikTok. Her bariatric surgery context is relevant, her description of appetite suppression tracks with the pharmacology, and she's not making cure claims or dosing recommendations. The gaps are around side effect expectations and oversimplifying the mechanism as purely physical restriction. Worth watching with that context in mind.